Vivos Therapeutics (VVOS) Short term Debt (2019 - 2026)
Vivos Therapeutics (VVOS) reported Short term Debt of $7.3 million for Q1 2026, down 12.62% on a QoQ basis from $8.4 million in Q4 2025.
Vivos Therapeutics (VVOS) has 5 years of Short term Debt data on file, last reported at $7.3 million in Q1 2026.
- Quarterly Short term Debt changed N/A year-over-year to $7.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.3 million (changed N/A YoY) and the FY2025 annual result came in at $8.4 million, changed N/A from the prior year.
- Short term Debt retreated to $7.3 million in Q1 2026 per VVOS's latest filing, from $8.4 million in the prior quarter.
- Across five years, Short term Debt topped out at $8.4 million in Q4 2025 and bottomed at $157000.0 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Vivos Therapeutics | 9.87 Mn | 7.64 Mn | 3.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.30 Mn |
| Dec 31, 2025 | 8.35 Mn |
| Sep 30, 2025 | 339,000.00 |
| Jun 30, 2025 | 157,000.00 |
| Dec 31, 2021 | 1.27 Mn |
| Sep 30, 2021 | 1.27 Mn |
| Jun 30, 2021 | 1.27 Mn |
| Mar 31, 2021 | 1.16 Mn |
| Dec 31, 2020 | 867,000.00 |
| Dec 31, 2019 | 3.71 Mn |